Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylone in Post-Traumatic Stress Disorder
NCT05741710Phase 2Completed
- Sponsor
- Transcend Therapeutics
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Methylone with Placebo (2 arms). Primary endpoint: Clinician-Administered PTSD Scale for DSM-5 Total Severity Score at 10 weeks. Started Mar 2023; status: completed.
02
Drugs
methylone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05741710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741710.